In recombinant human nicotinic receptor assays, galantamine hydrobromide did not significantly potentiate ACh-evoked currents in the tested oocyte systems. HEK293 cells expressing human α7 receptors likewise showed no positive modulation at 10 nM–10 µM; higher concentrations inhibited responses. These findings limit claims of nicotinic potentiation in these models. [2]
Electric-eel AChE inhibition
Biochemical assay · Isolated Electrophorus electricus acetylcholinesterase, type VI-S [1]
Galantamine hydrobromide was the positive-control inhibitor in a modified Ellman assay. The reported IC50 is an assay endpoint, not a treatment dose.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.01–100 µg/mL positive-control concentration range
- Exposure duration
- 30 min pre-incubation at 37 °C; 20 min substrate reaction; 10 min color development
- Method
- Modified Ellman assay; electric-eel AChE; acetylthiocholine substrate; phosphate buffer pH 8; inhibition calculated relative to activity without inhibitor with matched negative-control subtraction.
- Vehicle
- Positive control in water for screening; serial dilutions in phosphate buffer for IC50 determination.
- Co-treatment
- None; galantamine tested alone as the positive control.
- Reported limits
- No IC50 confidence interval or distinction between technical and independent triplicates. No Adooq lot testing.
Methods and source locations
Compound reported in the paper: Galantamine hydrobromide; Compound label in the paper: Positive control
Results apply to the named hydrobromide reagent in this assay; supplier provenance does not establish Adooq use.
Results 2.2; Table 1; Figure 2; Methods 3.1, 3.3–3.4
Inhibition of acetylthiocholine hydrolysis: Modified Ellman assay, 412 nm; experiments in triplicates; no uncertainty interval for this IC50 is supplied in Table 1. — Table 1, galantamine hydrobromide row; Results 2.2; Figure 2 A–D
Competitive AChE inhibition in substrate-variation experiments
Biochemical assay · Electric-eel AChE with varied acetylthiocholine concentration [1]
The authors classified galantamine hydrobromide inhibition as competitive from substrate-variation kinetics and Lineweaver–Burk plots. The no-inhibitor condition was the comparator.
Literature-Reported Treatment Conditions
- Treatment concentration
- Galantamine hydrobromide 1 and 5 µg/mL; substrate 0.1–1.6 mM
- Exposure duration
- Shared screening method: 30 min inhibitor pre-incubation, 20 min substrate reaction and 10 min color development
- Method
- Substrate-variation kinetics with no-inhibitor comparison; 37 °C; 412 nm.
- Vehicle
- Phosphate buffer
- Co-treatment
- None; comparator inhibitors were separate conditions.
- Reported limits
- No Ki is reported for this adopted experiment; no independent confirmation of reversibility was extracted.
Methods and source locations
Compound reported in the paper: Galantamine hydrobromide; Compound label in the paper: Positive control
Results apply to the named hydrobromide reagent in this assay; supplier provenance does not establish Adooq use.
Results 2.4; Table 3; Figure 4A; Methods 3.1, 3.3, 3.6
Substrate-variation kinetic pattern: Lineweaver–Burk plots and Michaelis–Menten fitting; triplicates. — Results 2.4; Table 3; Figure 4A
Nicotinic receptor modulation in oocytes
Cell-based study · Human α7, (α4)3(β2)2, (α4)2(β2)3 and (α4)3(β4)2 nicotinic receptors expressed in Xenopus laevis oocytes [2]
No significant positive modulation of ACh-evoked peak currents was observed over the tested range. Higher concentrations inhibited currents. NS1738 produced detectable positive modulation at α7 as an assay control.
Literature-Reported Treatment Conditions
- Treatment concentration
- Galantamine 10 nM–100 µM; ACh controls: α7 and (α4)3(β2)2, 30 µM; (α4)2(β2)3, 1 µM; (α4)3(β4)2, 10 µM
- Exposure duration
- 30–40 s galantamine pre-incubation followed by 25–45 s co-application with ACh; timing depended on receptor type
- Method
- Two-electrode voltage clamp at −60 mV; Ca2+-free standard recording solution; peak currents normalized to prior ACh-only reference.
- Vehicle
- Water stock diluted freshly in saline
- Co-treatment
- ACh co-application; NS1738 tested separately as positive modulation control.
- Reported limits
- These are isolated-cell receptor measurements, not whole-animal efficacy. No robust inhibitory fit was possible for (α4)2(β2)3 at the tested maximum; no IC50 is assigned to that receptor.
Methods and source locations
Compound reported in the paper: Galantamine hydrobromide; Compound label in the paper: Galantamine
Results apply to the named hydrobromide reagent in this assay; supplier provenance does not establish Adooq use.
Figures 1–2; Methods: Oocyte electrophysiology, Experimental protocol for oocyte experiments, Data analysis and Materials; corresponding Results
ACh-evoked peak current relative to ACh alone: Two-electrode voltage clamp, −60 mV; ACh-only reference and NS1738 positive-modulator control at α7. — Results: Testing for modulatory properties of galantamine at nACh receptors expressed in oocytes; Figures 1–2
Human α7 receptor responses in HEK293 cells
Cell-based study · HEK293 cells stably expressing human wild-type α7 nicotinic receptor and RIC3 [2]
Galantamine did not positively modulate ACh-evoked currents at 10 nM–10 µM; inhibition was apparent at 100 µM. The fitted inhibitory IC50 was 64 µM (n = 7 experiments). NS1738 produced positive modulation in the same assay system.
Literature-Reported Treatment Conditions
- Treatment concentration
- Galantamine 10 nM–100 µM; ACh 80 µM (approximately EC20)
- Exposure duration
- 40 s pre-application (60 s at 0.01 µM galantamine), then 250 ms co-application with ACh
- Method
- Whole-cell patch clamp at −70 mV; ACh-only reference; NS1738 positive-modulator control tested separately.
- Vehicle
- Fresh dilutions in recording buffer
- Co-treatment
- ACh co-application; NS1738 tested separately.
- Reported limits
- n denotes complete cell experiments, not animals; datasets obtained on at least two experimental days. No clinical concentration or efficacy inference.
Methods and source locations
Compound reported in the paper: Galantamine hydrobromide; Compound label in the paper: Galantamine
Results apply to the named hydrobromide reagent in this assay; supplier provenance does not establish Adooq use.
Figure 5 A–D; Methods: HEK293 cell patch-clamp electrophysiology, Data analysis and Materials; corresponding Results
Inhibition of ACh-evoked α7 peak current: Whole-cell patch clamp; Hill fit to peak-current responses normalized to prior ACh-only control. IC50 is fitted inhibitory potency, not the applied dose. — Figure 5C; Results: Testing for modulatory properties of galantamine at α7 nACh receptors expressed in HEK293 cells